Provided by Tiger Trade Technology Pte. Ltd.

DiaMedica Therapeutics Inc.

6.53
+0.01430.22%
Volume:55.81K
Turnover:361.26K
Market Cap:352.08M
PE:-9.13
High:6.57
Open:6.53
Low:6.32
Close:6.52
52wk High:10.42
52wk Low:5.14
Shares:53.88M
Float Shares:28.20M
Volume Ratio:0.55
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7157
EPS(LYR):-0.7000
ROE:-114.62%
ROA:-64.12%
PB:9.18
PE(LYR):-9.33

Loading ...

Company Profile

Company Name:
DiaMedica Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
35
Office Location:
301 Carlson Parkway,Suite 210,Minneapolis,Minnesota,United States
Zip Code:
55305
Fax:
- -
Introduction:
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Directors

Name
Position
Rick Pauls
Chief Executive Officer and Director and President
James Parsons
Chair of the Board and Director
Charles Semba
Director
Daniel O Connor
Director
Michael Giuffre
Director
Richard Kuntz
Director
Tanya Lewis
Director

Shareholders

Name
Position
Rick Pauls
Chief Executive Officer and Director and President
Scott Kellen
Chief Financial Officer and Secretary
Julie Krop
Chief Medical Officer